Highlights Valneva

Equities

Market Closed - Euronext Paris Other stock markets 11:37:24 2024-05-10 EDT			After market 15:59:56
3.364 ^EUR	+3.32%		3.345	-0.56%

05-07	Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-07	Transcript : Valneva SE, Q1 2024 Earnings Call, May 07, 2024

Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Valneva: quarterly results boosted by PRV sale	05-07	CF
Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024	05-07	CI
Valneva: Deep Track Biotechnology Master holds less than 5% of the capital	04-11	CF
Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate	03-26	MT
Valneva: Phase 1 trial initiated in the Zika virus	03-26	CF
Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	03-26	CI
ADRs End Higher; XTL Biopharmaceuticals Climbs 129%	03-20	DJ
Valneva SE Raises Revenue Guidance for 2024	03-20	CI
Valneva SE Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Valneva: share price down, forecasts below expectations	03-20	CF
French biotech company Valneva raises product sales guidance	03-20	RE
U.S. CDC Advisory Committee Recommends Use of Valneva?s Single-Dose Chikungunya Vaccine IXCHIQ	02-29	CI
Valneva: Ixchiq vaccine recommended by ACIP	02-29	CF
Valneva Se Announces Earnings Guidance for 2024	02-15	CI
Valneva: 26% increase in product sales in 2023	02-15	CF
VALNEVA : Oddo BHF confirms its recommendation on the stock	02-05	CF
Valneva Sells Tropical Disease Priority Review Voucher for $103 Million	02-05	MT
Valneva Sells Chikungunya Virus Vaccine’s Priority Review Voucher for $103 Million	02-05	MT
Valneva: sale of priority review warrant for Ixchiq	02-05	CF

No results for this search